The Emmes Group

The Emmes Group is an 18 year old consulting firm with offices in Boston and San Francisco. The Emmes Group is a strategic business development, assessment and planning organization specializing in the support of firms engaged in the technology, internet, biotechnology and pharmaceutical industries. Our partners have over 50 years of combined experience in serving technology, internet and healthcare companies. Our client list is an impressive list of some of the leading companies in the world.

Edward Weiner, , President & CEO

Mr. Weiner has over 30 years of successful experience in general management, business development, marketing, market research and technical sales. He has contributed significantly in all the operational and strategic support roles he has filled for such companies as 3M, Bio-Rad Laboratories, Millipore, and Waters, and while consulting for: Bayer, Bristol-Myers Squibb, Bayer, Genzyme, Haemonetics, Hewlett-Packard, Beckman, Perkin-Elmer, Varian, Shimadzu, Mettler-Toledo, PE Applied Biosystems, and dozens of other major corporations worldwide.

Martin Schroeder, Executive Vice President & Managing Director

Mr. Schroeder has over 25 years of successful experience in general management, technical R&D management, marketing, corporate finance and business development. Mr. Schroeder has contributed to the success of companies such as @POS, Dow Chemical, Immunex, Medicine Planet, Cyrano Sciences, Gamera Bioscience, MetaXen, Vistagen, Bethesda Pharmaceuticals, Acacia Biosciences, Maxim Biotech, Invivogen, Optigon Technology, Primex Physics International,,,, NH Ventures and the Ohio State University Office of Technology Transfer.

Steve Peltzman, Vice President

Mr. Peltzman has thirty plus years of business experience in companies spanning a spectrum of health care technologies from biopharmaceuticals to medical devices and diagnostics. From 1984 until 1991, he helped start and served as President and CEO of Applied bioTechnology, Inc., whose cancer business was sold to OSI Pharmaceuticals (OSIP NASDAQ; a.k.a. Oncogene Science). In 1991, he became Chief Operation Officer of the consolidated entity; from 1994 through 1997, he served as president and COO of OSI Pharmaceuticals and remained on its Board of Directors through 1999. From 1986 to 1990, Mr. Peltzman also was President of Oncogenetics Partners, a Joint Venture between Applied bioTechnology and E.I. du Pont de NeMours and Company, which focused on development of products relating to the prevention, treatment, and diagnosis of cancer. From 1980 to 1984, Mr. Peltzman held a number of senior executive positions with Millipore, and for the ten years preceding his position at Millipore, was with Corning’s Medical businesses – specializing in blood gas analysis. During the past several years he has been involved in several small, healthcare, and technology companies as their interim CEO and/or COO. Mr. Peltzman is active in TEC, a global organization of 6500 CEO's.

Nancy Hsiung, Ph.D., Vice President

Dr. Hsiung has broad experience in operations, business development as well as venture capital investments in the biopharmaceutical industry. Her responsibilities and achievements have included basic research in molecular and cellular biology, establishment and management of a tissue culture facility, licensing and technology assessment, project management, GMP pilot plant design, and development and introduction of a research detection kit. Dr. Hsiung’s investment experience included a role as a special advisor to the GeneChem Technologies Venture Fund for two years. Dr. Hsiung’s major strengths include strong analytical command, effective interpersonal skills, in-depth and extensive knowledge of the biopharmaceutical business, coupled with solid interviewing and analysis skills. Dr. Hsiung has a solid and successful track record of establishing new functions and procedures, and developing new business in many life science and technical start-up venture companies. Dr. Hsiung is the author of 26 publications abstracts; 4 US patents, and 2 US patent applications.

Charles Keough, Vice President

Charles Keough has over 20 years of experience in the healthcare industry, in both medical informatics and biotechnology. He is presently the founder and Principal of BioPharma Services, Inc. (BPSI), a life sciences advisory and consulting firm founded in 1997 to provide a range of strategic planning, operations, business development, technology assessment, market research and financing services for venture companies. Mr. Keough has spent most of his career working in small and start-up companies, managing finance, business development, and operational activities. From 1994-1997, Mr. Keough was an Investment Manager for JAFCO America Ventures, where he sourced and managed investments across the life sciences industry in the US. From 1990-1993, he was a consultant for the Nomura Research Institute in Tokyo working on cross-border alliances and market entry strategies for foreign (i.e., non-Japanese) medical and biotechnology companies. From 1982-1990, Mr. Keough worked with several leading vendors in the medical and hospital information systems field in both technical and senior management roles.

Bill Mitchell, Vice President

Mr. Mitchell has over thirty years of successful experience in general management, technical marketing, and business development. He has held numerous executive positions during his career with Abbott, Waters and I-Worx. Mr. Mitchell heads up the Emmes Group’s field and telephone market research operations.

Alexander Gelf, Principal

Alexander Gelf has more than 20 years of experience in the hi-tech industry with the background in software engineering, IT infrastructures, payment and mobile technologies, and information security. Mr. Gelf spent more than 10 years with Sun Microsystem, Inc. where he participated in developing Java technologies. Mr. Gelf served as a VP Information Technology for Hypercom Corp, a leading provider of POS hardware, where he oversaw a successful transition of Hypercom to a more efficient internal IT infrastructure and reducing its IT related OpEx. Mr. Gelf managed the successful deployment of a fare payment system based on NFC technologies for a rapid transit authority in a major European city.Mr. Gelf is a PMI certified Project Management Professional (PMP).

Richard Brounstein, Managing Director

Mr. Brounstein has over thirty years of operational and CFO-level financial leadership expertise with emerging growth companies within the software and life science/bio-tech/medical device areas and other tech companies. His background includes a range of companies from Fortune 500 to high-growth entrepreneurial opportunities. Over the past decade+, he has built an expertise dealing with the challenges of Smaller Public Companies. Mr. Brounstein brings to the group exceptional financial officer and governance expertise. His areas of knowledge include: SEC Compliance, Sarbanes-Oxley (SOX) support, XBRL, equity planning, asset management, and as a senior trusted advisor to his clients.

He was a member of the elite SEC Advisory Committee on Smaller Public Companies and is currently on the task force updating the COSO standards widely used in today’s SOX404 internal control compliance for SEC Reporting Companies. Mr. Brounstein practiced for seven years with Big ‘4’ accounting firms and has a CPA certificate. He holds a BA in Accounting (honors) and an MBA in Finance (high-honors) from the Michigan State University.

Contact Information:

West Coast Office
The Emmes Group, Inc.
92 Natoma Street, Suite 200
San Francisco, CA 94105
Tel: (415) 495-7111
FAX: (415) 495-3777

East Coast Office
The Emmes Group, Inc.
803 Wisteria Way
Wayland, MA 01778
Tel: (508) 358-2221
FAX: (508) 358-2882

Note:  Please be aware that the Emmes Group is in no way affiliated with The Emmes Company, LLC.